RSS

Munidpharma

Pharmaceutical and biotech partnering company Mundipharma, is set to launch Truxima, the first biosimilar monoclonal antibody authorised by the European Comission (EC) for the treatment of cancers. more

News

Mundipharma Early Development in Oncology (EDO) has announced the initiation of a first-in-human clinical trial of its investigational drug candidate EDO-S101 for relapsed-refractory (RR) cancer treatment more

News

Findings presented at the EORTC, EANO and ESMO congress in Istanbul demonstrate that EDO-S101 is effective in models of human glioblastoma irrespective of methyltransferase status and in combination with radiotherapy. more

News

The data shows the efficacy and tolerability of flutiform, a combination of fluticasone propionate and formoterol in a single pressurised metered dose inhaler, over 12 weeks in children with asthma aged 5 to <12. more

Mundipharma’s network of independent associated companies has been extended to form a new company called Mundipharma EDO (Early Development in Oncology) with the purpose of building a robust and sustainable pipeline in oncology. more

New addition: Mundipharma’s network of independent associated companies has been extended to form a new company called Mundipharma EDO. more

Home